Invesco Ltd. Sells 947,128 Shares of Evolent Health, Inc $EVH

Key Points

• Invesco Ltd. significantly cut its holdings in Evolent Health, Inc by 84.9% during the first quarter, now owning approximately 0.14% of the company's shares valued at $1.6 million.
• Multiple analysts have set new price targets for Evolent Health, with the average target reaching $18.07, reflecting a general consensus rating of "Buy."
• Evolent Health reported a loss of $0.10 EPS in its latest earnings, missing expectations, while its revenue decreased by 31.3% year-over-year.

Invesco Ltd. cut its stake in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 84.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 168,493 shares of the technology company's stock after selling 947,128 shares during the period. Invesco Ltd. owned about 0.14% of Evolent Health worth $1,596,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Evolent Health by 18.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,498 shares of the technology company's stock worth $346,000 after purchasing an additional 5,712 shares during the period. Brighton Jones LLC purchased a new stake in Evolent Health in the 4th quarter worth about $3,927,000. Brevan Howard Capital Management LP purchased a new stake in Evolent Health in the 4th quarter worth about $613,000. Hussman Strategic Advisors Inc. increased its holdings in Evolent Health by 66.7% in the 1st quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the technology company's stock worth $994,000 after acquiring an additional 42,000 shares during the last quarter. Finally, US Bancorp DE grew its holdings in Evolent Health by 291.0% during the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock valued at $49,000 after buying an additional 3,835 shares in the last quarter.

Evolent Health Trading Up 1.2%

EVH stock traded up $0.12 during midday trading on Friday, hitting $9.61. The company had a trading volume of 2,016,991 shares, compared to its average volume of 3,679,526. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. Evolent Health, Inc has a 52 week low of $7.06 and a 52 week high of $31.80. The stock's 50 day moving average price is $10.04 and its 200 day moving average price is $9.53. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -5.97 and a beta of 0.73.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The company had revenue of $444.33 million during the quarter, compared to the consensus estimate of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business's revenue for the quarter was down 31.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts expect that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EVH. Truist Financial lifted their target price on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Piper Sandler lifted their price target on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. JMP Securities reiterated a "market outperform" rating and set a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. Needham & Company LLC reiterated a "buy" rating and set a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Finally, UBS Group lifted their price target on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Evolent Health currently has a consensus rating of "Buy" and an average target price of $18.07.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.